Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Virginie Herve (Tours, France), Christophe Epinette, Clémence Henry, Eric Morello, Delphine Fouquenet, Thomas Baranek, Lise Vanderlynden, Jérôme Montharu, Francis Gauthier, Mustapha Si-Tahar, Virginie Herve. Histidinylated polylysines: An alternative antibacterial and fluidifying agent in cystic fibrosis.**. Eur Respir J 2015; 46: Suppl. 59, 2060

Member's Comments

No comment yet.

Related content which might interest you: Alternating inhaled antibiotic therapy in CF: A single center analysis Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015 Anaerobic bacteria and host defence in cystic fibrosis Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013 Efficacy and safety of inhaled antibiotics for chronic pseudomonas infection in cystic fibrosis: Network meta-analysis Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016 Early eradication of pseudomonas aeruginosa (PA) in cystic fibrosis patients (CF): Which is the best treatment? Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013 Novel antiviral properties of vitamin D in cystic fibrosis airway epithelial cells Source: International Congress 2014 – Cystic fibrosis: assessment and treatment Year: 2014 Formulation of dual modality nanoparticles to enhance tobramycin efficacy in cystic fibrosis Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways Year: 2013 Antiviral activity of azithromycin in cystic fibrosis airway epithelial cells Source: International Congress 2014 – Cystic fibrosis: assessment and treatment Year: 2014 The oral AntibioticS approprIateness score (OASIS) – A novel scoring system to assess antibiotic route in pulmonary exacerbations of cystic fibrosis (CF) Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013 Possible mechanisms of action of azithromycin in cystic fibrosis Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005 The characteristics of the minimum inhibitory concentration of antibiotics on pulmonary infections in patients with cystic fibrosis Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 Potential therapeutic use of 12-Lipoxygenase inhibitors in the treatment of mucus overproduction in cystic fibrosis Source: Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease Year: 2009 Perflubron enhances mucin plug clearance in vitro in the presence of natural surfactant Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Lung Clearance Index (LCI) and FEV1 on the evaluation of the effect of tobramycin solution for inhalation (TIS) among patients with cystic fibrosis Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment Year: 2014 Resistance to antimicrobial agents in patients with non-cystic fibrosis (CF) bronchiectasis Source: Eur Respir J 2005; 26: Suppl. 49, 640s Year: 2005 Inhaled heparin in cystic fibrosis Source: Eur Respir J 2006; 27: 354-358 Year: 2006 Surfactant dysfunction in cystic fibrosis: Mechanisms and reversal with a cyclodextrin drug Source: International Congress 2016 – Cystic fibrosis: monitoring and management Year: 2016 Emerging pathogens in cystic fibrosis Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=66 Year: 2006 A randomised comparison of two tobramycin formulations in cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) infection for pharmacokinetic and therapeutic equivalence Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013 Effectiveness and adherence to treatment with nebulized colistimethate sodium (Promixin®) in non-cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa (PsA) Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook Year: 2015 Azoles therapeutic drug monitoring and fungal antimicrobial resistance in adults with Cystic Fibrosis Source: International Congress 2018 – Latest developments in cystic fibrosis Year: 2018